Clinical Trial: Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Stud
Brief Summary: The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Detailed Summary:
Sponsor: AbbVie (prior sponsor, Abbott)
Current Primary Outcome:
- CAARS:Inv [ Time Frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]
- CGI-ADHD-S [ Time Frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- CAARS:Self [ Time Frame: Day -1, Day 14, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]
- BRIEF-A [ Time Frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24 ]
- AAQOL [ Time Frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24 ]
- WPAI [ Time Frame: Day -1, Month 3, 6, 9, 12, 15, 18, 21, 24 ]
- FTND [ Time Frame: Day -1, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24 ]
Original Secondary Outcome: Same as current
Information By: AbbVie
Dates:
Date Received: May 28, 2008
Date Started: May 2008
Date Completion:
Last Updated: January 11, 2013
Last Verified: January 2013